Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSCW


Primary Symbol: ENSC

Healthcare Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

Accesswire November 16, 2023

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

Accesswire November 9, 2023

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

Accesswire October 24, 2023

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Accesswire October 18, 2023

Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium

Accesswire October 13, 2023

Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023

Accesswire October 3, 2023

Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

Accesswire September 26, 2023

Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023

Accesswire September 19, 2023

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

Accesswire September 14, 2023

Ensysce Presents "A New Generation of Safer Pain Treatments"

Accesswire September 7, 2023

Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Accesswire September 5, 2023

Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium

Accesswire August 14, 2023

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

Accesswire August 11, 2023

Ensysce Biosciences Announces IRB Approval of Key Study Protocol

Accesswire August 8, 2023

Ensysce Biosciences Announces Engagement of Alacrita Consulting

Accesswire July 26, 2023

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

Accesswire June 27, 2023

Ensysce Biosciences Regains Compliance with Nasdaq

Accesswire June 13, 2023

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website

Accesswire June 7, 2023

Ensysce Biosciences to Participate in Upcoming Industry Events

Accesswire June 6, 2023

Ensysce Biosciences Reports First Quarter 2023 Financial Results

Accesswire May 15, 2023